2018 Compounding Policy Priorities Plan

Regulatory Compliance Associates® Inc. (RCA) has been following the U.S. Food and Drug Administration (FDA) and their position as it relates to compounding facilities. On January 18, 2018, Scott Gottlieb, Commissioner of the FDA, issued it’s 2018 Compounding Policy Priorities Plan. The Plan outlines how the agency will implement certain key aspects of the Drug Quality and Security Act (DQSA) and other provisions of the law relevant to compounders.

 

The Plan identified five key areas the agency intends to address before the end of 2018 to continue implementation of regulations and policy governing oversight of compounding pharmacies and outsourcing facilities:

 

  • Address manufacturing standards for outsourcing facilities
  • Regulate compounding from bulk drug substances
  • Restrict compounding of drugs that are essentially copies of FDA-approved drugs
  • Solidify the FDA’s partnership with state regulatory authorities
  • Provide guidance on other activities that compounders undertake

 

As part of the implementation of the plan, FDA also issued three final guidance documents explaining its policies on provisions of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and the finalized Guidance on Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application.

 

Since enactment of the DQSA, the FDA has conducted nearly 500 inspections, issued more than 180 warning letters advising compounders of significant violations of federal law, issued more than 70 letters referring inspectional findings to state regulatory agencies, overseen more than 150 recalls involving compounded drugs and worked with the Department of Justice (DOJ) on multiple civil and criminal enforcement actions.

 

Don’t be part of the statistics. RCA can help your company strategically address regulatory issues and help you establish a robust quality system designed to meet current FDA expectations for compounding pharmacies out outsourcing facilities. To learn more, fill out the short form on the bottom of the page and we will contact you shortly. 

I'm Interested in Learning More About RCA

*=Required

News

Insights on Phase Appropriate GMP for Biological Processes: Pre-clinical to Commercial Production...
Read More

News

Insights on Phase Appropriate GMP for Biological Processes: Pre-clinical to Commercial Production...
Read More

News

Insights on Phase Appropriate GMP for Biological Processes: Pre-clinical to Commercial Production...
Read More
PDA Midwest Chapter – Regulatory Submissions & Changes...
Read More
2018 Compounding Policy Priorities Plan...
Read More